Results 121 to 130 of about 19,107 (245)

Varenicline for smoking cessation [PDF]

, 2007
Serena Tonstad
openalex   +2 more sources

α7‐Nicotinic Acetylcholine Receptor and Mutated α‐Synuclein Interact in Motor Behaviour and Nigrostriatal Dopamine—Findings With Potential Relevance for a Protective Effect of Cigarette Smoking and Parkinson's Disease

European Journal of Neuroscience, Volume 61, Issue 6, Page 1-11, March 2025.
Mice with a mutated human α‐synuclein were crossed with mice lacking the nicotinic α7‐acetylcholine receptor; offsprings were analysed for signs of Parkinson's disease. Mice with mutated α‐synuclein without α7‐acetylcholine receptor had an asymmetry of nigral cell counts and an increased striatal dopamine turnover apart from some motor impairments ...
Christian Pifl, Alexandra Wolf, Mark Elevado, Petra Scholze   +3 more
wiley   +1 more source

2532

Journal of Clinical and Translational Science, 2017
OBJECTIVES/SPECIFIC AIMS: The central goal is to predict the metabolites of varenicline and predictively evaluate their propensities for eliciting an increased binding effect in the brain.
Keeshaloy Thompson, Milton Brown
doaj   +1 more source

Heteromeric nicotinic receptors are involved in the sensitization and addictive properties of MDMA in mice [PDF]

, 2013
We have investigated the effect of nicotinic receptor ligands in the behavioral sensitization (hyperlocomotion) and rewarding properties (conditioned place preference paradigm, CPP) of 3,4-methylenedioxy-methamphetamine (MDMA) in mice.
Camarasa García, Jordi, Ciudad Roberts, Andrés, Escubedo Rafa, Elena, Pubill Sánchez, David   +3 more
core   +2 more sources

Drug-induced liver injury due to varenicline: a case report

BMC Gastroenterology, 2012
Background Liver injury due to prescription and nonprescription medications is an expanding public health concern in the United States, with drug-induced liver injury (DILI) being the single most common reason for regulatory actions instituted by the ...
Sprague David, Bambha Kiran
doaj   +1 more source

Risk of neuropsychiatric adverse events associated with varenicline:systematic review and meta-analysis [PDF]

, 2015
Objective To determine the risk of neuropsychiatric adverse events associated with use of varenicline compared with placebo in randomised controlled trials. Design Systematic review and meta-analysis comparing study effects using two summary estimates in
Gunnell, David, Higgins, Julian P T, Knipe, Duleeka W, Martin, Richard M, Thomas, Kyla H   +4 more
core   +1 more source

The science does not yet support regulatory approval of amyloid‐targeting therapies for Alzheimer's disease based solely on biomarker evidence

Alzheimer's &Dementia, Volume 21, Issue 4, April 2025.
Vincent Planche, Suzanne Schindler, David S. Knopman, Giovanni Frisoni, Douglas Galasko, Joshua D. Grill, Lon Schneider, Jason Karlawish, Nicolas Villain   +8 more
wiley   +1 more source

New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What has been Investigated and What is in the Pipeline? [PDF]

, 2016
A wide range of support is available to help smokers to quit and aid attempts at harm reduction, including three first-line smoking cessation medications: nicotine replacement therapy, varenicline and bupropion.
A Bisaga, A Jackson, A Kukkar, A Lenox-Smith, A Mann, A Parsons, A Sood, A Sood, A Verrotti, AE Evins, AH Glassman, AK Shinn, AM Joseph, AR Buchhalter, AS Rauhut, AV Prochazka, B Gaster, B Pasternak, B Spring, B Westenberger, BA Johnson, BF Grant, BM Kuehn, C Bullen, C Lerman, C Reavill, C Zona, C-Y Yeh, CA Martin, CD Cropp, CE Gartner, CF Koegelenberg, CL Bennett, CL DeVane, CL Strasinger, CT Bolliger, D Gonzales, D Hammond, D Kotz, D Kotz, D Kotz, D Mischoulon, D Moore, DA Baker, DA Baltieri, DA Revicki, Damian M. Cummings, DE Hilleman, DJ Romberger, DK Hatsukami, DK Hatsukami, DK Miller, DP Tashkin, E Beard, E Beard, E Beard, E Gere-Pászti, E Nowakowska, EA Finkelstein, EA Gilpin, EA McClure, EA Zimovetz, EC Westman, ED Levin, EG Guy, EH Cerny, EJ Jensen, EJ Mills, EJ Mills, EJ Wagena, Emma Beard, EW Tuan, F Wang, FT Filippidis, G Addolorato, G Chiara Di, G Cucchiaro, G Sutherland, GA Higgins, GM Keating, H Kitagawa, H McRobbie, H McRobbie, H Minami, H Myrick, H Pine-Abata, H-J Aubin, HM Schuller, I Berlin, J Balmford, J Brown, J Cornuz, J Foulds, J Foulds, J Kaper, J Kay, J Leaviss, J Ollivier, J Rose, J Shearer, J Shearer, J Yang, J-F Etter, J-G Gehricke, JA Dani, JE Henningfield, JE Henningfield, JE Rose, JE Rose, JE Sarginson, JF Rosenbaum, JM Ramon, JM Samet, JN Liberman, JO Ebbert, JO Ebbert, JR DiFranza, JR Hughes, JR Hughes, JS Ballon, JS Brown, JS Fowler, JW Lockner, K Bolin, K Demyttenaere, K Hara, K Ogita, K Silla, KA Holes-Lewis, KA Kasza, KA Perkins, KA Sacco, KC Waterman, KE Dunn, KE Farsalinos, KH Thomas, KP Garnock-Jones, KS Paudel, L Annemans, L Kozlowski, L Leggio, L Lima De, L Schmaal, L Shahab, L Shahab, LF Gaal Van, LH Ferry, Lion Shahab, LS Brose, LS Brose, LS Covey, M Farrell, M Harrison-Woolrych, M Hoogendoorn, M Khalifa, M Lader, M Mahmoudi, M McCarty, M Mugnaini, M Mula, M Neovius, M Ng, M Pravetoni, M Pravetoni, M Raw, M Raw, M Sofuoglu, M Sofuoglu, M Sofuoglu, M Sofuoglu, M Williams, M Wimbiscus, MA Jacobs, MA Russell, MA Russell, MC Fiore, ME Hadwiger, ME Jarvik, ME Jarvik, ME Mooney, ME Page, ME Thase, MFG Murphy, MG LeSage, MG LeSage, MH Ebell, MH Rapaport, ML Goniewicz, MM Moran, MY Bertram, N Benowitz, N Lindblom, N Walker, N Woolacott, NB Edwards, NF Woolacott, NL Benowitz, P Aveyard, P Farid, P Franks, P Gerrard, P Hajek, P Hajek, P Hajek, P Hajek, P Jha, P Maurer, P Popik, PH Hoogsteder, PH Silverstone, PM Bet, PM Cinciripini, PS Masand, R Benyamin, R Freedman, R Niaura, R Niaura, R Ray, R Richmond, R Shytle, R Taylor, R West, R West, R West, R West, R West, R West, R West, RA Brown, RA Schnoll, RA Schnoll, RB Barlow, RC Smith, RD Hurt, RD Hurt, RE Fahim, RF Yoshimura, RM Anthenelli, RM Pinder, Robert West, S Brimijoin, S Denford, S Greenland, S Leonard, S Shiffman, S Shiffman, S Shiffman, S Shiffman, S Singh, S Thornley, S Tonstad, S Tonstad, S Wanwimolruk, SA Ornish, SC Licata, SD Hall, SD Satoskar, SE Adkison, SH Villiers de, SL McElroy, SM Boekholdt, SM Holliday, SP Lakshmi, SS Hecht, Susan Michie, T Blondal, T Green, T Paparrigopoulos, T Raupach, TB Johnstone, TE Langley, TE Meyer, TJ Meine, TL Awtry, TM Luger, TR Franklin, U Eckstein-Ludwig, U Perngparn, V Butterweck, V Gligorijevic, V Klimek, V Varga, V Vengeliene, VS Kumar, W Berrettini, W Hao, W Pichayakorn, W Qiumei, WI Najm, WR Hiatt, X Shen, Y Buggy, Y Khazaal, Y-S Kim   +293 more
core   +1 more source

Guideline for pharmacological treatment of schizophrenia 2022

Neuropsychopharmacology Reports, Volume 45, Issue 1, March 2025.
Japanese Society of Neuropsychopharmacology, Japanese Society of Clinical Neuropsychopharmacology   +1 more
wiley   +1 more source

Varenicline Reduces Alcohol Intake During Repeated Cycles of Alcohol Reaccess Following Deprivation in Alcohol-Preferring (P) Rats [PDF]

, 2017
Background Most alcoholics experience periods of voluntary alcohol abstinence or imposed alcohol deprivation followed by a return to alcohol drinking.
Dilley, Julian E., Filosa, Nick J., Froehlich, Janice C., Nicholson, Emily R., Rademacher, Logan C., Smith, Teal N.   +5 more
core   +1 more source